Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adherence, patient preference and dosing frequency: understanding the relationship.

J Y Reginster1, V Rabenda, A Neuprez

  • 1WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, University of Liège, Liège, Belgium. jyreginster@ulg.ac.be

Bone
|March 8, 2006
PubMed
Summary

Improving osteoporosis treatment adherence is crucial. A once-monthly bisphosphonate regimen, like ibandronate, is preferred by patients over weekly dosing, enhancing convenience and lifestyle integration for better therapeutic outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re: Bobelyak M, Vaculik J, Stepan JJ. Bone mineral density assessment using Radiofrequency Echographic Mult Spectrometry (REMS) in patients before and after total hip replacement, Osteoporos Int 2025;https://doi.org/10.1007/s00198-025-07685-w and Re: Pocock N, Chan D. Editorial: Is REMS-BMD truly a measured parameter? A call for transparency and technical clarification, Osteoporos Int 2025;https://doi.org/10.1007/s00198-025-07699-4.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Latin American patients' perceptions on osteoporosis diagnosis and treatment: The IOF Patient Advisory Group in Latin America.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Patient perceptions of osteoporosis management: a qualitative pilot study by a patient advisory group.

Archives of osteoporosis·2025
Same author

Assessing gait parameters with accelerometer-based methods to identify older adults at risk of falls: a systematic review.

European geriatric medicine·2021
Same author

Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort.

Public health·2021
Same author

Osteoporosis in Frail Older Adults: Recommendations for Research from the ICFSR Task Force 2020.

The Journal of frailty & aging·2021

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Patient Adherence

Background:

  • Suboptimal treatment adherence in chronic diseases, including osteoporosis, leads to poor outcomes and increased healthcare costs.
  • Osteoporosis management is challenging due to its asymptomatic nature and limited patient self-monitoring tools.
  • Current oral bisphosphonates, while first-line therapy, have strict dosing and potential gastrointestinal side effects, leading to ~50% discontinuation within a year.

Purpose of the Study:

  • To address the need for improved patient adherence in osteoporosis treatment.
  • To evaluate the impact of reduced bisphosphonate dosing frequency on therapeutic adherence.
  • To assess patient preference for once-monthly versus weekly bisphosphonate dosing schedules.

Main Methods:

Related Experiment Videos

  • Review of studies assessing bisphosphonate dosing frequency and patient adherence.
  • Analysis of patient preference data comparing once-monthly and weekly dosing regimens.
  • Evaluation of patient-reported reasons for dosing schedule preferences.

    • Main Results:

    • Weekly bisphosphonate dosing improves adherence compared to daily administration, but remains suboptimal.
    • A significant majority of patients (67-71%) prefer a once-monthly dosing schedule over weekly.
    • Key reasons for preference include better lifestyle integration (49-77%) and convenience (75%).

    Conclusions:

    • A once-monthly bisphosphonate regimen, such as ibandronate, shows potential to enhance patient adherence.
    • Improved adherence can lead to longer treatment duration and better overall therapeutic effectiveness for osteoporosis.
    • Novel dosing strategies are needed to overcome adherence barriers in chronic disease management.